Recently, monoclonal antibodies targeting CTLA-4 (Ipilimumab and Tremelimumab), PD-1 (Nivolumab, Pembrolizumab, and Pidilizumab), and PD-L1 (Avelumab, Atezolizumab, and Durvalumab) have already acquired US Food and Drug Administration (FDA) approval for the treatment of highly metastatic melanoma and metastatic non-small cell lung carcinoma, while others are still undergoing clinical and pre-clinical trials [3]. This evidence concerns the gene CD274 and metastatic melanoma.